Biosensors for Cardiac Biomarkers
Cardiovascular diseases (CVDs) are the leading national cause of death, impacting nearly 92.1 million Americans and accounting for 801,000 deaths annually. Unfortunately, CVDs are clinically silent until serious complications arise, thus allowing CVDs to go undetected or even be misdiagnosed at earlier stages. In addition, while biomarker testing and other cardiovascular tests can lead to earlier diagnoses, these tests are usually not ordered unless the probability of the patient having a CVD is high due to the expenses, effort, and time required. Therefore, a rapid point-of-care device would be highly useful for screening CVD conditions. This research effort was designed to fabricate a biosensing platform using aptamers and electrochemical impedance spectroscopy to rapidly detect two of the most prominent CVDs, myocardial infarction (MI) and congestive heart failure (CHF). To detect these two diseases, we screened for corresponding biomarkers Troponin T (TnT) and Brain Natriuretic Peptide (BNP). The results demonstrated preliminary efficacy of fabricated biosensor platforms in both serum and whole blood.
Components of a biosensor.
1. BIOSENSORS AND BIOELECTRONICS, vol. 77, pp. 580-588 (2016).
2. ACS BIOMATERIALS SCIENCE AND ENGINEERING, vol. 2, pp. 712-721 (2016).